Shares of Cara Therapeutics Inc (NASDAQ:CARA) have been assigned an average recommendation of “Buy” from the seventeen brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $25.75.

Several research analysts have recently weighed in on CARA shares. Scotiabank upped their price target on shares of Cara Therapeutics from $31.00 to $31.50 and gave the stock an “outperform” rating in a report on Tuesday, October 17th. ValuEngine cut shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. BidaskClub raised shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 2nd. Raymond James Financial upped their target price on shares of Cara Therapeutics from $25.00 to $26.00 and gave the stock a “market perform” rating in a research report on Tuesday, November 7th. Finally, Zacks Investment Research lowered shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th.

In related news, CEO Derek T. Chalmers sold 16,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $12.66, for a total value of $202,560.00. Following the completion of the transaction, the chief executive officer now directly owns 1,066,292 shares in the company, valued at $13,499,256.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.50% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in CARA. Vanguard Group Inc. boosted its position in Cara Therapeutics by 17.4% during the second quarter. Vanguard Group Inc. now owns 1,107,874 shares of the biopharmaceutical company’s stock valued at $17,050,000 after buying an additional 164,247 shares during the period. Gotham Asset Management LLC purchased a new stake in Cara Therapeutics during the second quarter valued at about $448,000. C WorldWide Group Holding A S boosted its position in Cara Therapeutics by 76.6% during the third quarter. C WorldWide Group Holding A S now owns 291,341 shares of the biopharmaceutical company’s stock valued at $3,988,000 after buying an additional 126,330 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Cara Therapeutics during the third quarter valued at about $451,000. Finally, Swiss National Bank purchased a new stake in Cara Therapeutics during the second quarter valued at about $651,000. Institutional investors own 58.64% of the company’s stock.

Cara Therapeutics (CARA) opened at $12.43 on Tuesday. The firm has a market cap of $405.32, a price-to-earnings ratio of -5.43 and a beta of 2.96. Cara Therapeutics has a 1-year low of $10.25 and a 1-year high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). During the same period in the previous year, the company earned ($0.42) EPS. equities analysts predict that Cara Therapeutics will post -1.84 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Cara Therapeutics Inc (CARA) Given Average Recommendation of “Buy” by Brokerages” was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/09/cara-therapeutics-inc-cara-given-average-recommendation-of-buy-by-brokerages.html.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.